Polyamine analogues: An update

Heather Mann Wallace, Kirsi M Niiranen

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The polyamines are growth factors in both normal and cancer cells. As the intracellular polyamine content correlates positively with the growth potential of that cell, the idea that depletion of polyamine content will result in inhibition of cell growth and, particularly tumour cell growth, has been developed over the last 15 years. The polyamine pathway is therefore a target for development of rationally designed, antiproliferative agents. Following the lessons from the single enzyme inhibitors (a-difluoromethylornithine DFMO), three generations of polyamine analogues have been synthesised and tested in vitro and in vivo. The analogues are multi-site inhibitors affecting multiple reactions in the pathway and thus prevent the up-regulation of compensatory reactions that have been the downfall of DFMO in anticancer chemotherapy. Although the initial concept was that the analogues may provide novel anticancer drugs, it now seems likely that the analogues will have wider applications in diseases involving hyperplasia.
Original languageEnglish
Pages (from-to)261-265
Number of pages5
JournalAmino Acids
Volume33
Issue number2
Early online date19 Apr 2007
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Polyamines
Cell growth
Growth
Eflornithine
Chemotherapy
Enzyme Inhibitors
Hyperplasia
Tumors
Neoplasms
Intercellular Signaling Peptides and Proteins
Up-Regulation
Cells
Drug Therapy
Pharmaceutical Preparations

Keywords

  • cancer
  • spermidine
  • spermine
  • polyamine analogues
  • DFMO
  • disease

Cite this

Polyamine analogues : An update. / Wallace, Heather Mann; Niiranen, Kirsi M.

In: Amino Acids, Vol. 33, No. 2, 08.2007, p. 261-265.

Research output: Contribution to journalArticle

Wallace, Heather Mann ; Niiranen, Kirsi M. / Polyamine analogues : An update. In: Amino Acids. 2007 ; Vol. 33, No. 2. pp. 261-265.
@article{81606b43d38748f283d474c30ec0cff3,
title = "Polyamine analogues: An update",
abstract = "The polyamines are growth factors in both normal and cancer cells. As the intracellular polyamine content correlates positively with the growth potential of that cell, the idea that depletion of polyamine content will result in inhibition of cell growth and, particularly tumour cell growth, has been developed over the last 15 years. The polyamine pathway is therefore a target for development of rationally designed, antiproliferative agents. Following the lessons from the single enzyme inhibitors (a-difluoromethylornithine DFMO), three generations of polyamine analogues have been synthesised and tested in vitro and in vivo. The analogues are multi-site inhibitors affecting multiple reactions in the pathway and thus prevent the up-regulation of compensatory reactions that have been the downfall of DFMO in anticancer chemotherapy. Although the initial concept was that the analogues may provide novel anticancer drugs, it now seems likely that the analogues will have wider applications in diseases involving hyperplasia.",
keywords = "cancer, spermidine, spermine, polyamine analogues , DFMO, disease",
author = "Wallace, {Heather Mann} and Niiranen, {Kirsi M}",
year = "2007",
month = "8",
doi = "10.1007/s00726-007-0534-z",
language = "English",
volume = "33",
pages = "261--265",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "SPRINGER WIEN",
number = "2",

}

TY - JOUR

T1 - Polyamine analogues

T2 - An update

AU - Wallace, Heather Mann

AU - Niiranen, Kirsi M

PY - 2007/8

Y1 - 2007/8

N2 - The polyamines are growth factors in both normal and cancer cells. As the intracellular polyamine content correlates positively with the growth potential of that cell, the idea that depletion of polyamine content will result in inhibition of cell growth and, particularly tumour cell growth, has been developed over the last 15 years. The polyamine pathway is therefore a target for development of rationally designed, antiproliferative agents. Following the lessons from the single enzyme inhibitors (a-difluoromethylornithine DFMO), three generations of polyamine analogues have been synthesised and tested in vitro and in vivo. The analogues are multi-site inhibitors affecting multiple reactions in the pathway and thus prevent the up-regulation of compensatory reactions that have been the downfall of DFMO in anticancer chemotherapy. Although the initial concept was that the analogues may provide novel anticancer drugs, it now seems likely that the analogues will have wider applications in diseases involving hyperplasia.

AB - The polyamines are growth factors in both normal and cancer cells. As the intracellular polyamine content correlates positively with the growth potential of that cell, the idea that depletion of polyamine content will result in inhibition of cell growth and, particularly tumour cell growth, has been developed over the last 15 years. The polyamine pathway is therefore a target for development of rationally designed, antiproliferative agents. Following the lessons from the single enzyme inhibitors (a-difluoromethylornithine DFMO), three generations of polyamine analogues have been synthesised and tested in vitro and in vivo. The analogues are multi-site inhibitors affecting multiple reactions in the pathway and thus prevent the up-regulation of compensatory reactions that have been the downfall of DFMO in anticancer chemotherapy. Although the initial concept was that the analogues may provide novel anticancer drugs, it now seems likely that the analogues will have wider applications in diseases involving hyperplasia.

KW - cancer

KW - spermidine

KW - spermine

KW - polyamine analogues

KW - DFMO

KW - disease

U2 - 10.1007/s00726-007-0534-z

DO - 10.1007/s00726-007-0534-z

M3 - Article

VL - 33

SP - 261

EP - 265

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

IS - 2

ER -